Evidence map›Paper›PMID 35832710›Full record

ArticleArchives of medical science : AMS2022

The effects of rivaroxaban, an oral anticoagulant, on human IVD primary cultures.

Tezcan Caliskan, Hande Akalan, Ibrahim Yilmaz, Numan Karaarslan, Duygu Yasar Sirin, Hanefi Ozbek

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Tezcan CaliskanDepartment of Neurosurgery, School of Medicine, Namik Kemal University, Tekirdag, Turkey.
Hande AkalanDepartment of Molecular Biology and Genetics, Faculty of Arts and Sciences, Namik Kemal University, Tekirdag, Turkey.
Ibrahim YilmazDepartment of Medical Pharmacology, School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Numan KaraarslanDepartment of Neurosurgery, School of Medicine, Halic University, Istanbul, Turkey.
Duygu Yasar SirinDepartment of Molecular Biology and Genetics, Faculty of Arts and Sciences, Namik Kemal University, Tekirdag, Turkey.
Hanefi OzbekDepartment of Medical Pharmacology, Bakircay University School of Medicine, Izmir, Turkey.
Tekirdağ Namık Kemal University · TRHaliç University · TRIstanbul Medipol University · TRIzmir University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The present study aimed to investigate the potential effects of rivaroxaban, an oral anticoagulant that inhibits the effects of factor Xa, on intact intervertebral disc tissue cells and the extracellular matrix (ECM). Material and methods: Rivaroxaban was applied to primary human cell cultures prepared from tissues of the intervertebral disc. Comparative molecular analyses were performed on non-drug-treated control group samples. Descriptive statistics were presented as the mean ± standard deviation. An analysis of variance test was performed to determine whether there were significant differences in the mean across the groups. When differences across groups were observed, Tukey's honestly significant difference post-hoc test was used for multiple pairwise comparisons. The significance of the obtained data was determined statistically. The α significance value was < 0.05. Results: The cells in the control group and in the rivaroxaban-treated group were viable, healthy, and proliferated ( Conclusions: Although rivaroxaban does not suppress cell proliferation due to morphological, biological, and biochemical changes in the intervertebral disc tissue, it may change the expression of genes that are related to ECM maintenance.

Indexed as

cartilage oligo matrix proteinchondroadherin genecytotoxicityintervertebral disc cellsmatrix metalloproteinasesnucleus pulposusrivaroxaban

Identifiers

PMID35832710
PMCPMC9266726
OpenAlexW3162317134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.